Indirect Treatment Comparisons of Lisocabtagene Maraleucel Versus Axicabtagene Ciloleucel and Tisagenlecleucel in Third-Line or Later Relapsed or Refractory Follicular Lymphoma

Lymphoma

Comparative outcomes of lisocabtagene maraleucel versus an external control arm in third-line or later relapsed or refractory follicular lymphoma

Leuk Lymphoma

Nastoupil LJ, Martín García-Sancho A, Izutsu K, Cartron G, Zausner Skarbnik AP, Reguera Ortega JL, Goto H, Borchmann P, Farazi T, Bar M, Del Rosario Olivera M, Kumar J, De Benedetti M, Gu F, Stein D, Han J, Palomba ML

doi: 10.1080/10428194.2026.2650672

Lymphoma

Zanubrutinib versus acalabrutinib indirect treatment comparison in relapsed or refractory mantle cell lymphoma

Leuk Lymphoma

Shah B, Challagulla S, Xu S, Williams R, Ren S, Srivastava T, Gautam R, Yang K, Saba NS, Tam CS

doi: 10.1080/10428194.2025.2541911

Lymphoma

Lisocabtagene Maraleucel Versus Standard of Care for Second-Line Relapsed/Refractory Large B-Cell Lymphoma: 3-Year Follow-Up From the Randomized, Phase III TRANSFORM Study

J Clin Oncol

Kamdar M, Solomon SR, Arnason J, Johnston PB, Glass B, Bachanova V, Ibrahimi S, Mielke S, Mutsaers P, Hernandez-Ilizaliturri F, Izutsu K, Morschhauser F, Lunning M, Chow VA, Montheard S, Santamaria J, Colicino S, Ogasawara K, Stepan L, Liu FF, Abramson JS

doi: 10.1200/JCO-25-00399

Lymphoma

Epcoritamab, lenalidomide, and rituximab versus lenalidomide and rituximab for relapsed or refractory follicular lymphoma (EPCORE FL-1): a global, open-label, randomised, phase 3 trial

Lancet

Falchi L, Nijland M, Huang H, Linton KM, Seymour JF, Tao R, Kwiatek M, Costa A, Vassilakopoulos TP, Greil R, Jiménez-Ubieto A, Gangatharan SA, Benjamini O, Thieblemont C, Tucci A, Elinder-Camburn A, Illes A, Novak J, Pavlovsky MA, McDonald A, Yoon DH, Maruyama D, Sunkersett G, Mei JP, Mukherjee N, Zhu F, Alshreef A, Favaro E, Morschhauser F, EPCORE FL-1 Investigators

doi: 10.1016/S0140-6736(25)02360-8

Lymphoma

Real-world outcomes for lisocabtagene maraleucel in patients with relapsed or refractory large B-cell lymphoma

Blood

Crombie JL, Ahmed S, Frigault MJ, Hunter BD, Palomba ML, Mirza AS, Lunning MA, Egini O, Odstrcil Bobillo MS, Kallam A, Kambhampati Thiruvengadam S, Lee D, Dahiya S, Hamadani M, Herrera AF, Lee CJ, Patel K, Patel SS, Reagan PM, Shadman M, Bernasconi D, Kim S, Liu FF, Roy D, Pasquini MC, Isufi I

doi: 10.1182/blood.2025031733

Leukemia

Pirtobrutinib Versus Ibrutinib in Treatment-Naïve and Relapsed/Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma

J Clin Oncol

Woyach JA, Qiu L, Grosicki S, Wrobel T, Capra M, Czyz J, Yi S, Eom KS, Panovská A, Jurczak W, Laribi K, Jacobasch L, Baker R, Agajanian R, Berkovits A, Özcan M, Lepretre S, Coombs CC, Cramer P, Lewis KL, Hill M, Bao K, Bian Y, De Batista Ribeiro SR, Bhandari NR, Ruppert AS, Leow CC, Wierda WG

doi: 10.1200/JCO-25-02477

Lymphoma

Tafasitamab, lenalidomide, and rituximab in relapsed or refractory follicular lymphoma (inMIND): a global, phase 3, randomised controlled trial

Lancet

Sehn LH, Hübel K, Luminari S, Scholz CW, Salar A, Paneesha S, Wahlin BE, Panayiotidis P, Lee HP, Jiménez-Ubieto A, Sancho JM, Kim TM, Domingo Domenech E, Kumode T, Poh C, Thieblemont C, Deeren D, de Wit E, Arbushites M, Vassallo I, Trneny M, inMIND Study team

doi: 10.1016/S0140-6736(25)01778-7

Lymphoma

Circulating Tumor DNA Assessment of Disease Response in Large B-Cell Lymphoma: Lisocabtagene Maraleucel Versus Autologous Stem Cell Transplantation Standard Therapy

J Clin Oncol

Stepan L, Ansari S, Abramson JS, Okal A, Dell'Aringa J, Thompson EG, Crotta A, Chow VA, Kamdar M, Solomon SR, Johnston PB, Glass B, Mutsaers P, Arnason J, Mielke S, Shadman M, Hernandez-Ilizaliturri F, Izutsu K, Bachanova V, Ibrahimi S, Chabon JJ, Kurtz DM, Alizadeh AA, Peiser L

doi: 10.1200/JCO-25-03051

Lung, Respiratory and Thoracic Cancer

A matching-adjusted indirect comparison of first-line lorlatinib and alectinib for the treatment of ALK-rearranged advanced non-small cell lung cancer

Eur J Cancer

Byun JY, Kim J, Park S, Sun JM, Lee SH, Ahn JS, Ahn MJ, Kim JH, Lee EK, Jung HA

doi: 10.1016/j.ejca.2025.115805

Related content

Comparative outcomes of lisocabtagene maraleucel versus an external control arm in third-line or later relapsed or refractory follicular lymphoma

Zanubrutinib versus acalabrutinib indirect treatment comparison in relapsed or refractory mantle cell lymphoma

Lisocabtagene Maraleucel Versus Standard of Care for Second-Line Relapsed/Refractory Large B-Cell Lymphoma: 3-Year Follow-Up From the Randomized, Phase III TRANSFORM Study

Epcoritamab, lenalidomide, and rituximab versus lenalidomide and rituximab for relapsed or refractory follicular lymphoma (EPCORE FL-1): a global, open-label, randomised, phase 3 trial

Real-world outcomes for lisocabtagene maraleucel in patients with relapsed or refractory large B-cell lymphoma

Pirtobrutinib Versus Ibrutinib in Treatment-Naïve and Relapsed/Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma

Tafasitamab, lenalidomide, and rituximab in relapsed or refractory follicular lymphoma (inMIND): a global, phase 3, randomised controlled trial

Circulating Tumor DNA Assessment of Disease Response in Large B-Cell Lymphoma: Lisocabtagene Maraleucel Versus Autologous Stem Cell Transplantation Standard Therapy

A matching-adjusted indirect comparison of first-line lorlatinib and alectinib for the treatment of ALK-rearranged advanced non-small cell lung cancer